Is Moderna Overvalued? A Look At The Economics of Vaccines

Published on
September 27th, 2021
Duration
65 minutes

Evergrande and the Global Economy — What Will Be the Ripple Effects?


Is Moderna Overvalued? A Look At The Economics of Vaccines

Live ·
Featuring Damien Conover and Jack Farley

Published on: September 27th, 2021 • Duration: 65 minutes

Most companies producing COVID-19 vaccines have appreciated substantially in the past year—from new biotech companies like Moderna and BioNTech SE, who rely heavily on the vaccine for revenues, to established players like AstraZeneca and Johnson & Johnson, which have pledged to sell their vaccines on a not-for profit level. Will the momentum keep going these biotech stocks? Damien Conover, managing director of healthcare equity research at Morningstar, shares his perspective on the biotech space and also breaks down his outlook for other companies like Sanofi, Merck, and Bayer AG. Interviewed by Jack Farley, who will be taking live questions from Real Vision Plus members.

Comments

Transcript